Search Results for "Mirrx Therapeutics"

21:41 EDT 23rd October 2016 | BioPortfolio

Matching Channels

Tuberculosis Vaccines and Therapeutics

The WHO estimates that the largest number of new tuberculosis (TB) cases in 2008 occurred in the South-East Asia Region, which accounted for 34% of incident cases globally. However, the estimated inci...


KIACTA™ (also known as eprodisate) is an orally bioavailable small molecule intended for the treatment of AA amyloidosis, an orphan indication that results from long-standing inflammatory cond...

Anthrax Vaccines and Therapeutics

Anthrax is a zoonotic disease caused by the spore-forming bacterium Bacillus anthracis. The disease most commonly occurs in mammals (e.g., cattle, sheep, goats, camels, antelope. Anthrax occurs in hu...


AUT00063 develpoed by Autifony Therapeutics, is a novel, orally active small molecule designed to selectively modulate Kv3 potassium channels, which are important in central auditory processing. Pre...

Facebook - BioPortfolio Pages

BioPortfolio has launched a number of Facebook pages to allow our visitors to keep track with latest news, published paper and clinical trials by lead biotechnology and healthcare topics:- &nbs...

Matching News

PX'Therapeutics und RELIEF THERAPEUTICS Holding AG kündigen strategischen Kooperationsvertrag für rekombinante Produktion von Atexakin Alfa an

PX'Therapeutics, Tochtergesellschaft des Aguettant Konzerns, ein Unternehmen, das sich auf die kundenspezifische Entwicklung rekombinanter Proteine konzentriert, und die RELIEF THERAPEUTICS Holdin...

Domain Therapeutics sets up Mavalon Therapeutics, with financial backing from Medicxi

French drug discovery company Domain Therapeutics today announced the creation of Mavalon Therapeutics,…

Seres Therapeutics, Emulate collaborate to support development of novel microbiome therapeutics

Seres Therapeutics, a microbiome therapeutics platform company, and Emulate, a private firm commercializing the Organs-on-Chips technology, announced a new collaboration.

Relief Therapeutics kündigt strategische Allianz mit PX'Therapeutics an

Genf/Grenoble (awp) - Das Biotechunternehmen Relief Therapeutics kündigt eine strategische Zusammenarbeit mit PX'Therapeutics an. Gemeinsam werden die beiden Unternehmen an der Produktion von Atexa.....

Antegrin and Cascadia merge to form Indalo Therapeutics

Antegrin Therapeutics and Cascadia Therapeutics have established Indalo Therapeutics, a biotechnology company dedicated to developing novel therapies to treat fibrotic diseases.

PX'Therapeutics and RELIEF THERAPEUTICS Holding AG Announce a Strategic Collaboration Agreement for the Recombinant Production of Atexakin Alfa

PX'Therapeutics, a subsidiary of the Aguettant group, a company that specializes in the customer-tailored development of recombinant proteins, and RELIEF THERAPEUTICS Holding AG ("Relief", SIX : R...

PX'Therapeutics et RELIEF THERAPEUTICS Holding AG annoncent un accord de collaboration stratégique pour la production recombinante d'atéxakine alfa

PX'Therapeutics, filiale du groupe Aguettant, société spécialisée dans la préparation sur mesure de protéines recombinantes, et RELIEF THERAPEUTICS Holding AG (« Relief », SIX : RLF), sociét...

BIND Therapeutics says Pfizer’s $40 million bid for its assets is the winner

US biotech firm BIND Therapeutics, a developer of targeted and programmable therapeutics called Accurins,…

Matching PubMed Articles

Injectable biomaterials: a perspective on the next wave of injectable therapeutics.

We are experiencing a new wave of injectable therapeutics (namely/injectable biomaterials) to complement injectable drugs and injectable biologics, and to serve as the basis for injectable combinatori...

Response #2 to Immediate Intraocular Pressure Tendency Following Intravitreal Delivery of Dexamethasone Implant; Alagöz et al. J. Ocul. Pharmacol. Ther. 32:44-49, 2016.

Comparison of Self-Reported and Objective Adherence to Antiglaucoma Medications.

Pigmentation and Macular Degeneration: Is There a Role for GPR143?

Fit for the Eye: Aptamers in Ocular Disorders.

For any new class of therapeutics, there are certain types of indications that represent a natural fit. For nucleic acid ligands in general, and aptamers in particular, the eye has historically been a...

Search Whole site using Google

Quick Search
Advertisement Advertisement